Clinical Benefit of Maintenance Therapy for Advanced Biliary Tract Cancer Patients Showing No Progression after First-Line Gemcitabine Plus Cisplatin

Jaewon HYUNG; Bumjun KIM; Changhoon YOO; Kyo-Pyo KIM; Jae-Ho JEONG; Heung-Moon CHANG; Baek-Yeol RYOO.
Cancer Research and Treatment ; : 901-909, 2019.
Artículo en Inglés | WPRIM | ID: wpr-763189

Documentos relacionados

  1. Rational development of combination therapies for biliary tract cancers.
  2. [Progress of genomic mutation spectrum in biliary tract malignant tumors].
  3. [Chinese expert consensus on the whole-course standardized management of biliary tract cancer(2023)].
  4. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial.
  5. The path to personalized treatment in advanced and metastatic biliary tract cancers: a review of new targeted therapies and immunotherapy.
  6. Hereditary cancer variants and homologous recombination deficiency in biliary tract cancer.
  7. A critical appraisal of the potential benefit of post-operative structured follow-up after resection for biliary tract cancer.
  8. Phase Ib study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis.
  9. Clinical Implications of BRCA Mutations in Advanced Biliary Tract Cancer.
  10. Prognostic Nutritional Index Associates with Immunotherapy Response in Patients with Metastatic Biliary Tract Cancer.